PROM1 and neoplasm: Hettich et al. reported that a CD3-bsAb targeting the tumor stem cell marker AC133 (a stem cell-specific epitope of CD133) stimulated apoptosis of hypo-fractionated radiotherapy-induced tumor-infiltrating lymphocytes (TILs) via the PD-1 pathway.